Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | B3GNT2 | Q9NY97 | 15/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891152 | 0.82 | ROCK2 (0.46) | B3GNT2KDM4EALDH1A1GLAGAA | |
| SCHEMBL891245 | 0.82 | KDM4E (0.48) | B3GNT2KDM4EALDH1A1GLAGAA | |
| SCHEMBL891547 | 0.81 | B3GNT2 (0.48) | B3GNT2KDM4EALDH1A1GLAGAA | |
| SCHEMBL15282191 | 0.81 | MAOB (0.38) | B3GNT2KDM4EALDH1A1GLAGAA | |
| SCHEMBL891255 | 0.80 | B3GNT2 (0.44) | B3GNT2KDM4EALDH1A1GLAGAA | |
| SCHEMBL891385 | 0.80 | B3GNT2 (0.51) | B3GNT2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1064027 | 0.80 | B3GNT2 (0.65) | B3GNT2KDM4EALDH1A1GAAHPGD | |
| SCHEMBL891155 | 0.79 | B3GNT2 (0.58) | B3GNT2ALDH1A1GAAMEN1RAB9A | |
| SCHEMBL891491 | 0.78 | ALDH1A1 (0.56) | B3GNT2KDM4EALDH1A1GLAGAA | |
| SCHEMBL890853 | 0.77 | POLB (0.48) | B3GNT2KDM4EALDH1A1MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268273-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2011-01-05 | — | — | EP | claimed |
| US-20120083493-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2012-04-05 | — | — | US | disclosed |
| EP-2268273-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083493-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | TRPC4, TRPC3, TRPC1 | B3GNT2 2182/4885KDM4E 3912/4885ALDH1A1 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.